Association between SLCO1B1 rs4149056 and tegafur-uracil-induced hepatic dysfunction in breast cancer

Kamio, Hidenori; Kamio, Takihiro; Shikama, K.; Nogami, Mako; Noguchi, Emiko; Ohchi, Tetsuya; Uchiyama, T.; Kanno, Hitoshi; Saito, Keiichi; Okamoto, Taro

doi:10.1016/s0960-9776(17)30143-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis revealed an association between the SLCO1B1 521T>C polymorphism and the risk of statin-induced adverse drug reactions including an abnormal alanine transaminase (ALT) level [23]. Another study including patients with breast cancer receiving tegafur-uracil also showed that patients with the CC or CT genotypes had higher risk of aspartate aminotransferase and ALT level elevation compared to those with the TT genotype [24]. These studies confirmed an association between the SLCO1B1 521T>C polymorphism and drug-induced hepatotoxicity.…”

Section: Discussionmentioning

confidence: 82%

Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: a systematic review and meta-analysis

Han

Choi

Lee³

et al. 2021

Anti-Cancer Drugs

View full text Add to dashboard Cite

Reports on the association between the solute carrier organic anion transporter 1B1 (SLCO1B1) T521C polymorphism and methotrexate-induced hepatotoxicity in patients with malignancies are inconsistent. This meta-analysis evaluated the association between the SLCO1B1 T521C polymorphism and methotrexateinduced hepatotoxicity. We performed a systematic review of previous reports from the PubMed, Web of Science, and EMBASE databases, and a meta-analysis was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated to evaluate the effect of the SLCO1B1 T521C polymorphism on the occurrence of methotrexate-induced hepatotoxicity. In total, data from five studies including 465 patients were analyzed. Patients had received a high-dose methotrexate regimen (1-5 g/m 2 ). The SLCO1B1 variant allele (C allele) carriers had a 1.9-fold higher risk of hepatotoxicity than wild-type homozygote carriers (TT; OR, 1.94; 95% CI, 1. 14-3.31). This meta-analysis demonstrated that C allele carriers of the SLCO1B1 polymorphism had a higher risk of hepatotoxicity than patients with the TT genotype. The SLCO1B1 T521C polymorphism may be a useful predictor for methotrexate-induced hepatotoxicity in patients with malignancies.

show abstract

Section: Discussionmentioning

confidence: 82%